Study summary
Adding orelabrutinib to first-line chemotherapy gave complete responses in most patients
87.1%complete response after induction
What was tested
Rituximab and high-dose methotrexate with orelabrutinib, a BTK inhibitor, for newly diagnosed PCNSL.
What they found
- Complete response after induction was 87.1%.
- 1-year progression-free survival was 83.6%.
What it means
Led to randomized trials of BTK inhibitors in first-line treatment.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.